Pediatric Infection and Vaccine

The Korean Society of Pediatric Infectious Diseases (대한소아감염학회)
권호 표지
DOI QR코드

DOI QR Code

Occurrence Pattern of Intussusception according to the Introduction of Rotavirus Vaccine: An Observational Study at a University Hospital

로타바이러스 백신 도입에 따른 장겹침증 발생 경향: 한 대학병원 관찰 연구

  • Nam, Hye Na (Department of Pediatrics, Gachon University Gil Medical Center, Gachon University College of Medicine) ;
  • Lim, Kyung In (Department of Pediatrics, Gachon University Gil Medical Center, Gachon University College of Medicine) ;
  • Tchah, Hann (Department of Pediatrics, Gachon University Gil Medical Center, Gachon University College of Medicine) ;
  • Ryoo, Eell (Department of Pediatrics, Gachon University Gil Medical Center, Gachon University College of Medicine) ;
  • Sun, Yong Han (Department of Pediatrics, Gachon University Gil Medical Center, Gachon University College of Medicine) ;
  • Cho, Hye-Kyung (Department of Pediatrics, Gachon University Gil Medical Center, Gachon University College of Medicine)
  • 남혜나 (가천대학교 의과대학 소아청소년과) ;
  • 임경인 (가천대학교 의과대학 소아청소년과) ;
  • 차한 (가천대학교 의과대학 소아청소년과) ;
  • 류일 (가천대학교 의과대학 소아청소년과) ;
  • 선용한 (가천대학교 의과대학 소아청소년과) ;
  • 조혜경 (가천대학교 의과대학 소아청소년과)
  • Received : 2016.06.22
  • Accepted : 2016.09.14
  • Published : 2016.12.25
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Rotavirus vaccine (RV) was introduced in Korea since 2007, and intussusception (IS) remains an important safety concern. This study investigated the trend of IS occurrence related to RV as well as the temporal relevance between vaccination and IS in children. Methods: We collected data of the patient aged ${\leq}18$ years with IS admitted to Gachon University Gil Medical Center, 2003 to 2015. For the patients that have occurred since 2008, the immunization records of RV were collected. The proportion of cases <1 year was calculated by the year and the temporal relationship between vaccination and IS occurrence was analyzed. Results: A total of 696 IS cases were noted. The cases <1 year were 30.7% (214/696). Although the incidence of all IS has increased over the 13-year period (from 74.1 in 2003 to 89.5 in 2015, linear by linear association, P=0.003), the incidence of IS <1 year has not increased (from 56.9 in 2003 to 53.3 in 2015, P=0.910), and the proportion of cases <1 year has decreased (from 35.4 in 2003 to 18.8 in 2015, P=0.000). Of 128 cases <1 year since 2008, 53.9% received RV. In the vaccinated group, 10 cases of IS occurred within 30 days, and eight cases did within 31 to 60 days. Numbers of IS after first, second, and third dose were three, 10, and five cases, respectively. Conclusions: Occurrence of IS in children <1 year of age did not increase since the introduction of RV. Further monitoring is essential for evaluation of vaccine safety.

목적: 2007년 로타바이러스 백신이 국내에 도입된 이후, 장겹침증은 백신 접종의 안전성과 관련하여 중요한 이슈 중 하나이다. 본 연구에서는 로타바이러스 백신 도입에 따른 장겹침증 발생 양상을 조사하여 우리나라 소아에서 로타바이러스 백신 접종과 장겹침증 발생 위험과의 관계를 알아보고자 하였다. 방법: 2003년부터 2015년까지 가천대학교 의과대학 길병원에 장겹침증으로 확진되어 입원 치료를 받은 18세 이하 환자들의 데이터를 조사하였다. 또한 2008년 이후에 장겹침증이 발생한 환자들에서는 로타바이러스 백신 접종력을 확인하였다. 매년 1세 미만 소아의 비율을 조사하였고, 백신 도입 이후 이들의 백신 접종과 장겹침증 발생 사이의 시간적 관계를 조사하였다. 결과: 장겹침증으로 입원한 소아 환자의 수는 총 696명이었고, 이 중 1세 미만은 30.7% (214/696)였다. 13년 동안 전체 소아청소년 장겹침증 환자의 발생률은 점차 증가하였으나(2003년 74.1 대 2015년 89.5, 선형 대 선형 결합, P=0.003) 1세 미만 장겹침증 환자의 발생률은 증가하지 않았고(2003년 56.9 대 2015년 53.3, 선형 대 선형 결합, P=0.910), 전체 소아청소년 장겹침증 환자 중 1세 미만 환자의 비율은 점차 감소하는 추세를 보였다(2003년 35.4 대 2015년 18.8, 선형 대 선형 결합, P=0.000). 2008년 이후에 발생한 1세 미만 장겹침증 환자 128명 중 로타바이러스 백신 접종 경력이 있었던 환자는 53.9% (n=69)이었다. 백신을 접종받았던 환자에서 증상 발생 30일 이내에 접종을 받았던 환자는 10명이었고 증상 발생 31-60일 이내에 접종을 받았던 환자는 8명이었다. 이들 18명 중 1차 접종 후에 증상이 발생한 경우가 3명, 2차 접종 후에 발생한 경우가 10명, 3차 접종 후에 발생한 경우가 5명이었다. 결론: 로타바이러스 백신 도입 이후 1세 미만 장겹침증 발생은 증가하지 않았지만 백신의 안전성을 평가하기 위한 지속적인 모니터링이 필요하다.

Keywords

References

  1. Bryce J, Boschi-Pinto C, Shibuya K, Black RE; WHO Child Health Epidemiology Reference Group. WHO estimates of the causes of death in children. Lancet 2005;365:1147-52. https://doi.org/10.1016/S0140-6736(05)71877-8
  2. Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006;12:304-6. https://doi.org/10.3201/eid1202.050006
  3. Dennehy PH. Rotavirus vaccines: an update. Vaccine 2007;25:3137-41. https://doi.org/10.1016/j.vaccine.2007.01.102
  4. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22. https://doi.org/10.1056/NEJMoa052434
  5. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33. https://doi.org/10.1056/NEJMoa052664
  6. Cortese MM, Parashar UD; Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009;58(RR-2):1-25.
  7. Than VT, Jeong S, Kim W. Characterization of RotaTeq(R) vaccine-derived rotaviruses in South Korean infants with rotavirus gastroenteritis. J Med Virol 2015;87:112-6. https://doi.org/10.1002/jmv.23975
  8. Park DK, Chung JY. The changes in the outbreak of rotavirus gastroenteritis in children after introduction of rotavirus vaccines: a retrospective study at a tertiary hospital. Korean J Pediatr Infect Dis 2014;21:167-73. https://doi.org/10.14776/kjpid.2014.21.3.167
  9. Sohn TY, Lee CJ, Kim YJ, Kang MJ, Kim SH, Lee SY, et al. Clinical and epidemiological study of 1,165 hospitalized cases of rotaviral gastroenteritis before and after the introduction of rotavirus vaccine, 2006-2013. Korean J Pediatr Infect Dis 2014;21:174-80.
  10. Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, Parashar UD. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010;201:1617-24. https://doi.org/10.1086/652403
  11. Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, Macartney KK, et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr Infect Dis J 2011;30(1 Suppl):S25-9. https://doi.org/10.1097/INF.0b013e3181fefdee
  12. Patel MM, Lopez-Collada VR, Bulhoes MM, De Oliveira LH, Bautista Marquez A, Flannery B, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011;364:2283-92. https://doi.org/10.1056/NEJMoa1012952
  13. Velazquez FR, Colindres RE, Grajales C, Hernandez MT, Mercadillo MG, Torres FJ, et al. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J 2012;31:736-44. https://doi.org/10.1097/INF.0b013e318253add3
  14. Yih WK, Lieu TA, Kulldorff M, Martin D, McMahill-Walraven CN, Platt R, et al. Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med 2014;370:503-12. https://doi.org/10.1056/NEJMoa1303164
  15. Buttery JP, Danchin MH, Lee KJ, Carlin JB, McIntyre PB, Elliott EJ, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011;29:3061-6. https://doi.org/10.1016/j.vaccine.2011.01.088
  16. Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001;344:564-72. https://doi.org/10.1056/NEJM200102223440804
  17. Belongia EA, Irving SA, Shui IM, Kulldorff M, Lewis E, Yin R, et al. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr Infect Dis J 2010;29:1-5. https://doi.org/10.1097/INF.0b013e3181af8605
  18. Haber P, Patel M, Izurieta HS, Baggs J, Gargiullo P, Weintraub E, et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics 2008;121:1206-12. https://doi.org/10.1542/peds.2007-3793
  19. Glass RI, Parashar UD. Rotavirus vaccines: balancing intussusception risks and health benefits. N Engl J Med 2014;370:568-70. https://doi.org/10.1056/NEJMe1315836
  20. Patel MM, Steele D, Gentsch JR, Wecker J, Glass RI, Parashar UD. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 2011;30(1 Suppl):S1-5. https://doi.org/10.1097/INF.0b013e3181fefa1f
  21. Carlin JB, Macartney KK, Lee KJ, Quinn HE, Buttery J, Lopert R, et al. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program. Clin Infect Dis 2013;57:1427-34. https://doi.org/10.1093/cid/cit520
  22. Bauchau V, Van Holle L, Mahaux O, Holl K, Sugiyama K, Buyse H. Post-marketing monitoring of intussusception after rotavirus vaccination in Japan. Pharmacoepidemiol Drug Saf 2015;24:765-70. https://doi.org/10.1002/pds.3800
  23. Lee YY, Lee EB, Choi KH. Difference in the distribution of onset age of intussusception after rotavirus vaccination and according to the type of rotavirus vaccine: single medical center study. Yeungnam Univ J Med 2015;32:80-4. https://doi.org/10.12701/yujm.2015.32.2.80
  24. Chungnam National University and Korea Centers for Disease Control and Prevention (KCDC). Korea National Immunization Survey. Seoul: Chungnam National University and KCDC, 2012.
  25. Yang HI, Park EY, Kim MY; Korea Centers for Disease Control and Prevention (KCDC). National immunization survey in South Korea, 2013. Public Health Wkly Rep 2013;7:449-54.